银屑病合并活动性或近期恶性肿瘤患者使用生物制剂的安全性与传统系统药物相当
该监测研究纳入333例银屑病合并活动性或近期(≤5年)恶性肿瘤患者,比较生物制剂与传统系统药物的安全性;中位随访6年,两组肿瘤进展/复发率及1年无进展生存率均无显著差异,生物制剂未增加癌症进展风险。
要点
- 生物制剂组与传统药物组肿瘤进展/复发率分别为10.7与10.5/100患者年。
核心结论
- 在银屑病合并活动性或近期恶性肿瘤患者中,生物制剂的使用是安全的,未增加癌症进展或复发风险。
研究设计与样本
- 监测研究,纳入333例银屑病合并活动性癌症或近期(≤5年)癌症病史的患者。
- 以接受传统系统药物治疗的患者作为对照。
- 共同主要结局包括无进展或复发生存期及严重感染发生率。
主要发现
- 中位随访6年,生物制剂组每100患者年进展/复发率为10.7,传统药物组为10.5。
临床怎么用
- 对于合并活动性或近期恶性肿瘤的银屑病患者,生物制剂可作为与传统系统药物安全性相当的治疗选择。
- 临床决策时应综合评估患者功能状态、癌症分期及合并症负担,这些因素与肿瘤进展或复发风险相关。
局限性
- 观察性设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited data exist on the safety of biologic agents in psoriasis patients with cancer, leading guidelines to recommend against their use within 5 years of cancer history. OBJECTIVE: To evaluate the safety of biologic therapies in psoriasis patients with active or recent (≤5 years) cancer. METHODS: A surveillance study of 333 cases with psoriasis and active cancer or a recent cancer history. Patients treated with conventional systemic agents served as comparators. Coprimary outcomes included progression- or recurrence-free survival and the incidence of severe infections. RESULTS: Over a median follow-up of 6 years, progression/recurrence rates per 100 patient-years were 10.7 (biologics) and 10.5 (conventional). The cumulative 1-year progression- or recurrence-free survival was 86% in both groups (P = .89). Overall, biologics did not affect cancer progression (hazard ratio, 1.02; 95% confidence interval, 0.59-1.77; P = .94). Predictors of progression or recurrence included impaired functional status, advanced cancer stage (hazard ratio per stage increment, 1.48; 95% confidence interval, 1.21-1.82; P < .001), and higher comorbidity burden. LIMITATIONS: Observational design. CONCLUSIONS: Biologics were safe to use in psoriasis patients with cancer.
引用
- Bar D, Brilant L, Lidar M, et al. Cancer progression, recurrence, and infection outcomes in psoriasis patients with active or recent malignancy treated with biologic therapy: A cohort study showing comparable safety to conventional agents. J Am Acad Dermatol. 2025. PMID: 41419137. doi:10.1016/j.jaad.2025.12.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。